Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor
Asher Mullard
Topics & Concepts
NodKRASPharmacologyMedicineComputational biologyCancer researchCancerBiologyDiabetes mellitusInternal medicineColorectal cancerEndocrinologyProtein Kinase Regulation and GTPase SignalingNeutrophil, Myeloperoxidase and Oxidative MechanismsCancer, Hypoxia, and Metabolism